Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“Denosumab every 12 weeks vs. every 4 weeks in mCRPC:
Lower risk of ONJ and tooth infections with q12w dosing.
Favorable long-term safety profile.
Could q12w become the new standard?”
More posts featuring Yüksel Ürün.